Animal and cell data only for MOTS-c itself; a company-reported Phase 1 of an analogue (CB4211) is the nearest human data
MOTS-c is a mitochondrial-encoded peptide identified in 2015 that improves metabolic markers and exercise capacity in mice through AMPK signalling. No controlled human trial of MOTS-c has been published. The closest human data are from CohBar's 2020–2021 Phase 1a/1b of CB4211, a modified analogue, which the company described as well tolerated with injection-site reactions; that description was a press release, not a paper.
Research-use information only. Research-grade MOTS-c is not an approved medicine; where trial or label figures appear below they belong to the pharmaceutical product studied, not to any research vial. This page does not give dosing or medical advice.
Every rate carries its source. Where no source exists, no rate is printed.
| Effect | Rate (sourced) | Detail | Source |
|---|---|---|---|
| Injection-site reactions | not quantified | Reported by the developer as the main adverse event in the CB4211 (analogue) Phase 1; unquantified in any publication. | CohBar company statements 2021 (not peer-reviewed) |
| Adverse effects in animal studies | not quantified | Not reported as a specific finding in the primary mouse studies; the studies were not designed as toxicology. | Lee et al. 2015; Reynolds et al. 2021 |
Regulatory status: Not approved anywhere; MOTS-c is on the WADA prohibited list (S4.4 metabolic modulators).
Everything above describes MOTS-c the molecule. The risk specific to a research vial is different: it may not contain MOTS-c at the labelled amount, and it may contain what the synthesis left behind. Identity (mass spectrometry), purity (HPLC), measured net content and an endotoxin result are the four lines on a certificate that bear on adverse effects, and only a certificate you can check at the laboratory tells you any of them. This is what we have verified for MOTS-c so far.
14 of the 77 vendors on our scoreboard list MOTS-c with a price we read on the product page (11 Sept 2026–2 Oct 2026). Of those, 11 name their testing laboratory, 7 publish certificates that resolve on the lab's own site, and 10 publish measured milligrams against the label. The full ranking, with every dated price, is on Best MOTS-c Vendors.
| Vendor | Rubric | Lab named | Price read |
|---|---|---|---|
| MyPurePeptidepartner | 10/10 | Janoshik Analytical | $45.00 · 40mg · 30 Sept 2026 |
| Purgo Labspartner | 10/10 | SteriGenix · Freedom Diagnostics | $49.99 · 10mg · 2 Oct 2026 |
| Amino Clubpartner | 9/10 | ILS Labs | $39.99 · 10mg · 2 Oct 2026 |
| Mile High Compounds | 8/10 | Kovera Labs · Chromate | $49.99 · 10mg · 11 Sept 2026 |
| Oros Research | 8/10 | Ethos Analytics | $39.99 · 10mg · 29 Sept 2026 |
Top 5 by rubric score; 9 more on the ranking page.
None yet for MOTS-c specifically. The COA library holds the certificates we have read for each vendor on other compounds, which is the next best signal of how that vendor documents a lot.
Not in a published controlled trial. A modified analogue (CB4211) went through Phase 1 in 2020–2021; the developer reported it as well tolerated with injection-site reactions, but no paper followed and the programme was later discontinued.